We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Merck is expecting a decision from the FDA in January on a supplemental NDA for its blockbuster oncology drug Keytruda (pembrolizumab) for treatment of high-risk, non-muscle invasive bladder cancer.